Abbott Laboratories $ABT Shares Sold by RB Capital Management LLC

RB Capital Management LLC trimmed its holdings in Abbott Laboratories (NYSE:ABT) by 0.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 40,165 shares of the healthcare product maker’s stock after selling 81 shares during the period. Abbott Laboratories comprises approximately 1.2% of RB Capital Management LLC’s holdings, making the stock its 17th largest holding. RB Capital Management LLC’s holdings in Abbott Laboratories were worth $5,328,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in ABT. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories in the first quarter valued at $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories in the 1st quarter valued at about $28,000. Elequin Capital LP acquired a new position in Abbott Laboratories in the first quarter worth about $30,000. Wormser Freres Gestion acquired a new stake in Abbott Laboratories during the fourth quarter valued at approximately $32,000. Finally, JCIC Asset Management Inc. bought a new position in Abbott Laboratories during the 1st quarter worth approximately $32,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT opened at $131.59 on Wednesday. The firm has a market capitalization of $229.03 billion, a price-to-earnings ratio of 16.49, a price-to-earnings-growth ratio of 2.50 and a beta of 0.70. The stock’s fifty day moving average is $131.03 and its 200-day moving average is $131.33. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the prior year, the firm posted $1.14 EPS. Abbott Laboratories’s revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date was Tuesday, July 15th. Abbott Laboratories’s dividend payout ratio is 29.57%.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.46% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ABT has been the topic of several research reports. Jefferies Financial Group raised Abbott Laboratories from a “hold” rating to a “buy” rating and upped their price target for the company from $143.00 to $145.00 in a research report on Friday, July 18th. Wells Fargo & Company cut their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a research note on Friday, July 18th. Evercore ISI boosted their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a report on Friday, July 18th. Finally, William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $144.47.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.